Cargando…

Synergistic Effect of Geranylgeranyltransferase Inhibitor, GGTI, and Docetaxel on the Growth of Prostate Cancer Cells

Most advanced prostate cancers progress to castration resistant prostate cancer (CRPC) after a few years of androgen deprivation therapy and the prognosis of patients with CRPC is poor. Although docetaxel and cabazitaxel can prolong the survival of patients with CRPC, inevitable progression appears...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Bin, Fujimoto, Naohiro, Kobayashi, Mizuki, Matsumoto, Tetsuro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195320/ https://www.ncbi.nlm.nih.gov/pubmed/22111007 http://dx.doi.org/10.1155/2012/989214

Ejemplares similares

Geranylgeranyltransferase I is essential for dendritic development of cerebellar Purkinje cells
por: Wu, Kong-Yan, et al.
Publicado: (2010)

Nanoformulation of Geranylgeranyltransferase-I Inhibitors for Cancer Therapy: Liposomal Encapsulation and pH-Dependent Delivery to Cancer Cells
por: Lu, Jie, et al.
Publicado: (2015)

Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI)
por: Adair, Jennifer E., et al.
Publicado: (2021)

Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells
por: Paolo, A Di, et al.
Publicado: (2001)

GGTase3 is a Newly Identified Geranylgeranyltransferase Targeting a Ubiquitin Ligase
por: Kuchay, Shafi, et al.
Publicado: (2019)

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer
por: Heinemann, Lucy, et al.
Publicado: (2011)

Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer
por: Li, Ke, et al.
Publicado: (2019)

In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells
por: Zimonjic, Drazen B, et al.
Publicado: (2013)

Synergistic anticancer activity of resveratrol in combination with docetaxel in prostate carcinoma cells
por: Lee, Sang-Han, et al.
Publicado: (2021)

Melanoma Cells Treated with GGTI and IFN-γ Allow Murine Vaccination and Enhance Cytotoxic Response against Human Melanoma Cells
por: Sarrabayrouse, Guillaume, et al.
Publicado: (2010)

Identification and Characterization of Mechanism of Action of P61-E7, a Novel Phosphine Catalysis-Based Inhibitor of Geranylgeranyltransferase-I
por: Chan, Lai N., et al.
Publicado: (2011)

Rab Geranylgeranyltransferase Subunit Beta as a Potential Indicator to Assess the Progression of Amyotrophic Lateral Sclerosis
por: Yang, Jing, et al.
Publicado: (2023)

Synergistic effects and mechanisms of impressic acid or acankoreanogein in combination with docetaxel on prostate cancer
por: Jiang, Sen, et al.
Publicado: (2018)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Undifferentiated prostate cancer treated with docetaxel
por: Kobayashi, Masaki, et al.
Publicado: (2020)

Synergistic Antitumor Activities of Docetaxel and Octreotide Associated with Apoptotic-Upregulation in Castration-Resistant Prostate Cancer
por: Zhu, Sha, et al.
Publicado: (2014)

Synergistic effect of a retinoid X receptor-selective ligand bexarotene and docetaxel in prostate cancer
por: Shen, Danyang, et al.
Publicado: (2019)

Aptamer‐conjugated mesoporous polydopamine for docetaxel targeted delivery and synergistic photothermal therapy of prostate cancer
por: Dai, Liang, et al.
Publicado: (2021)

Molecular and Pharmacological Characterization of the Interaction between Human Geranylgeranyltransferase Type I and Ras-Related Protein Rap1B
por: Hinz, Sonja, et al.
Publicado: (2021)

Synergistic Effect Of A Retinoid X Receptor-Selective Ligand Bexarotene And Docetaxel In Prostate Cancer [Corrigendum]
Publicado: (2019)

Genetic variations predicting progression with docetaxel and novel androgen‐receptor pathway inhibitors
por: Shiota, Masaki, et al.
Publicado: (2023)

Artesunate Inhibits the Growth Behavior of Docetaxel-Resistant Prostate Cancer Cells
por: Vakhrusheva, Olesya, et al.
Publicado: (2022)

γ-Klotho is correlated with resistance to docetaxel in castration-resistant prostate cancer
por: Onishi, Kenta, et al.
Publicado: (2020)

Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of Geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis
por: Chen, Shuzhen, et al.
Publicado: (2010)

Effects of Docetaxel plus Degarelix on Quality of Life and Vascular Endothelial Growth Factor in Patients with Prostate Cancer
por: Li, Weiping, et al.
Publicado: (2022)

Synergistic Enhancement of Cancer Therapy Using a Combination of Ceramide and Docetaxel
por: Feng, Li-Xia, et al.
Publicado: (2014)

A randomized phase III trial of personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel
por: Noguchi, Masanori, et al.
Publicado: (2021)

Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy
por: Ma, Zehua, et al.
Publicado: (2022)

Molecular mechanisms of docetaxel resistance in prostate cancer
por: Sekino, Yohei, et al.
Publicado: (2020)

The stem cell inhibitor salinomycin decreases colony formation potential and tumor‐initiating population in docetaxel‐sensitive and docetaxel‐resistant prostate cancer cells
por: Gruber, Martina, et al.
Publicado: (2019)

Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment
por: Brubaker, Kristen D, et al.
Publicado: (2006)

Shikonin Reduces Growth of Docetaxel-Resistant Prostate Cancer Cells Mainly through Necroptosis
por: Markowitsch, Sascha D., et al.
Publicado: (2021)

Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition
por: Iannelli, Federica, et al.
Publicado: (2020)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Computer-aided analysis of quercetin mechanism of overcoming docetaxel resistance in docetaxel-resistant prostate cancer
por: Omoboyede, Victor, et al.
Publicado: (2023)

Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer
por: Gravina, Giovanni Luca, et al.
Publicado: (2017)

KIFC1 Inhibitor CW069 Induces Apoptosis and Reverses Resistance to Docetaxel in Prostate Cancer
por: Sekino, Yohei, et al.
Publicado: (2019)

TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer
por: Sekino, Yohei, et al.
Publicado: (2019)

Overexpression of claspin promotes docetaxel resistance and is associated with prostate‐specific antigen recurrence in prostate cancer
por: Babasaki, Takashi, et al.
Publicado: (2021)

Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel‐sensitive and docetaxel‐resistant castration‐resistant prostate cancer cells
por: Li, Senmao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mdsqnm03bkhve930nkfvf5ipce